Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 281, 1-10
Abstract
No abstract availableKeywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (1569)
This publication has 57 references indexed in Scilit:
- The Prolyl Isomerase Pin1 Acts Synergistically with CDK2 to Regulate the Basal Activity of Estrogen Receptor α in Breast CancerPLOS ONE, 2013
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerJournal of Clinical Oncology, 2012
- Dissecting Pin1 and phospho‐pRb regulationJournal of Cellular Physiology, 2012
- High-grade serous ovarian cancer arises from fallopian tube in a mouse modelProceedings of the National Academy of Sciences, 2012
- Rethinking ovarian cancer: recommendations for improving outcomesNature Reviews Cancer, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancerOncogene, 2010
- Inhibition of the Peptidyl-Prolyl-Isomerase Pin1 Enhances the Responses of Acute Myeloid Leukemia Cells to Retinoic Acid via Stabilization of RARα and PML-RARαCancer Research, 2009
- Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stabilityMolecular Cancer, 2008
- Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast CancerCancer Research, 2008